The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Laktionov K.K.

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Breder V.V.

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Bolotina L.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia

Vladimirova L.Yu.

National Medical Research Center for Oncology of the Ministry of Health of Russia

Gordiev M.G.

OOO «NATIONAL BIOSERVICE»

Demidova I.A.

Moscow City Oncology Hospital No. 62

Moiseenko F.V.

Saint Petersburg Clinical Research and Practice Center of Specialized Medical Care in Oncology

Orlov S.V.

Acad. I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Reutova E.V.

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Savelov N.A.

Moscow City Oncology Hospital No. 62

Sakaeva D.D.

Bashkir State Medical University

Smolin A.V.

Acad. N.N. Burdenko Main Military Clinical Hospital of the Ministry of Defense of Russia

ALK-, ROS1-, RET-, and NTRK-positive non-small cell lung cancer: diagnosis and targeted therapy. Resolution of the Expert Panel

Authors:

Laktionov K.K., Breder V.V., Bolotina L.V., Vladimirova L.Yu., Gordiev M.G., Demidova I.A., Moiseenko F.V., Orlov S.V., Reutova E.V., Savelov N.A., Sakaeva D.D., Smolin A.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2021;10(4): 41‑43

DOI: 10.17116/onkolog20211004141

Views: 1476

Downloaded: 53

Download PDF (RU)
Contact the author
Table of contents

ALK-, ROS1-, RET-, AND NTRK-POSITIVE NON-SMALL CELL LUNG CANCER: DIAGNOSIS AND TARGETED THERAPY. RESOLUTION OF THE EXPERT PANEL
ALK-, ROS1-, RET-, AND NTRK-POSITIVE NON-SMALL CELL LUNG CANCER: DIAGNOSIS AND TARGETED THERAPY. RESOLUTION OF THE EXPERT PANEL

To cite this article:

Laktionov KK, Breder VV, Bolotina LV, et al. . ALK-, ROS1-, RET-, and NTRK-positive non-small cell lung cancer: diagnosis and targeted therapy. Resolution of the Expert Panel. P.A. Herzen Journal of Oncology. 2021;10(4):41‑43. (In Russ.)
https://doi.org/10.17116/onkolog20211004141

 
Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata
Recommended articles:
Mole­cularly targeted therapy for biliary cancer. P.A. Herzen Journal of Onco­logy. 2024;(3):34-39

In recent years, there has been a substantial increase in the number of available targeted molecular therapy options for different subtypes of advanced non-small cell lung cancer (NSCLC). In this connection, the availability of molecular genetic testing (MGT) is growing in importance for patients with NSCLC. On the other hand, the increase in the number of available targeted molecular treatment options for the already known mutations raises the question of the optimal sequence of their use in various groups of patients in clinical practice. The Expert Panel consisting of oncologists, pathologists, and geneticists gathered to develop recommendations, by using practical experience and taking into account the available scientific information on possible ways to improve the timely diagnosis of targeted mutations in patients with advanced NSCLC, as well as on the optimal sequence of targeted molecular therapy for patients with ALK-positive NSCLC.

Keywords:

NSCLC
ALK-positive
activating mutations
next-generation sequencing
targeted molecular therapy
alectinib
brigatinib
lorlatinib

Authors:

Laktionov K.K.

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Breder V.V.

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Bolotina L.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia

Vladimirova L.Yu.

National Medical Research Center for Oncology of the Ministry of Health of Russia

Gordiev M.G.

OOO «NATIONAL BIOSERVICE»

Demidova I.A.

Moscow City Oncology Hospital No. 62

Moiseenko F.V.

Saint Petersburg Clinical Research and Practice Center of Specialized Medical Care in Oncology

Orlov S.V.

Acad. I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Reutova E.V.

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Savelov N.A.

Moscow City Oncology Hospital No. 62

Sakaeva D.D.

Bashkir State Medical University

Smolin A.V.

Acad. N.N. Burdenko Main Military Clinical Hospital of the Ministry of Defense of Russia

Received:

29.06.2021

Accepted:

05.07.2021

List of references:

  1. Laktionov KK, Artamonova EV, Breder VV, Gorbunova VA, Moiseenko FV, Reutova EV, Sakaeva DD, Smolin AV, Ter-Ovanesov M.D. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu nemelkokletochnogo raka legkogo. Zlokachestvennye opukholi. 2019;9(3 suppl 2):32-48.  https://doi.org/10.18027 / 2224-5057-2019-9-3s2-32-48
  2. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D’Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, Hennon M, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Lovly CM, Martins RG, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Riely GJ, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Yanagawa J, Yang SC, Gregory KM, Hughes M. NCCN guidelines insights: non-small cell lung cancer. Version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254-266.  https://doi.org/10.6004/jnccn.2021.0013
  3. Yu TM, Morrison C, Gold EJ, Tradonsky A, Layton AJ. Multiple biomarker testing tissue consumption and completion rates with single-gene tests and investigational use of oncomine Dx target test for advanced non-small-cell lung cancer: a single-center analysis. Clin Lung Cancer. 2019;20(1):20-9.e8.  https://doi.org/10.1016/j.cllc.2018.08.010
  4. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020 Nov 19;383(21):2018-2029. https://doi.org/10.1056/NEJMoa2027187. PMID: 33207094.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.